Hillsdale Investment Management Inc. Lowers Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Hillsdale Investment Management Inc. lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 18.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 214,500 shares of the company's stock after selling 48,100 shares during the period. Hillsdale Investment Management Inc. owned approximately 0.10% of Hims & Hers Health worth $5,187,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $28,000. Raleigh Capital Management Inc. increased its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, US Bancorp DE grew its position in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 36,460 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares of the company's stock, valued at approximately $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 998,244 shares of company stock valued at $35,662,485. Insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $1.24 during trading on Tuesday, hitting $36.17. The company's stock had a trading volume of 10,964,663 shares, compared to its average volume of 22,585,061. The stock has a market cap of $8.04 billion, a price-to-earnings ratio of 82.29 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The stock has a 50-day moving average price of $39.44 and a two-hundred day moving average price of $29.05.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on HIMS. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target for the company. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Piper Sandler boosted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Finally, Truist Financial increased their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a report on Wednesday, February 26th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.